COVID-19 in teriflunomide-treated patients with multiple sclerosis

[1]  Yong Wang,et al.  Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2 , 2020, Protein & Cell.

[2]  V. Shaygannejad,et al.  COVID-19 infection in a patient with multiple sclerosis treated with fingolimod , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[3]  M. Sormani.  An Italian programme for COVID-19 infection in multiple sclerosis , 2020, The Lancet Neurology.

[4]  M. Inglese,et al.  COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? , 2020, Multiple Sclerosis and Related Disorders.

[5]  C. Eastin,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.

[6]  J. Lechner-Scott,et al.  The COVID-19 pandemic and the use of MS disease-modifying therapies , 2020, Multiple Sclerosis and Related Disorders.

[7]  Elisabeth Mahase.  Covid-19: what treatments are being investigated? , 2020, BMJ.

[8]  Ying Wang,et al.  COVID-19 infection: the perspectives on immune responses , 2020, Cell Death & Differentiation.

[9]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[10]  Hui Poh Goh,et al.  Treatment of COVID-19: old tricks for new challenges , 2020, Critical Care.

[11]  Honglin Li,et al.  Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2 , 2020, bioRxiv.

[12]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[13]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[14]  T. Olsson,et al.  Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. , 2020, JAMA neurology.

[15]  C. Tornatore,et al.  Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations , 2019, Neurology and Therapy.

[16]  Mei-jiao Gong,et al.  Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[17]  Ruth Ann Marrie,et al.  The prevalence of MS in the United States , 2019, Neurology.

[18]  Eugen C. Buehler,et al.  A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle , 2018, Genome Medicine.

[19]  F. Gilli,et al.  Treatment of Theiler’s virus-induced demyelinating disease with teriflunomide , 2017, Journal of NeuroVirology.

[20]  S. Kenney,et al.  Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication , 2017, Oncotarget.

[21]  V. Appay,et al.  Aging of the immune system: Focus on inflammation and vaccination , 2016, European journal of immunology.

[22]  E. Trinka,et al.  Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study , 2016, PloS one.

[23]  C. Lebrun.  The radiologically isolated syndrome. , 2015, Revue neurologique.

[24]  A. Bar-Or,et al.  Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[25]  A. Bar-Or,et al.  Teriflunomide and Its Mechanism of Action in Multiple Sclerosis , 2014, Drugs.

[26]  B. Kieseier,et al.  Teriflunomide for the treatment of multiple sclerosis , 2013, Clinical Neurology and Neurosurgery.

[27]  A. Bar-Or,et al.  Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis , 2013, Neurology.

[28]  J. Hillert,et al.  Hospital admission due to infections in multiple sclerosis patients , 2013, European journal of neurology.

[29]  Sun-Whe Kim,et al.  Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab , 2013, European journal of neurology.

[30]  W. V. van IJcken,et al.  Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates , 2010, PLoS pathogens.

[31]  C. Besada,et al.  Brain Atrophy in Radiologically Isolated Syndromes , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.